Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.33 |
| ▸ | TAF1 | P21675 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL771082 | 0.86 | — | — | |
| SCHEMBL4771249 | 0.80 | IRAK4 (0.36) | POLBALDH1A1 | |
| SCHEMBL27750226 | 0.76 | POLB (0.37) | POLBNCF1KAT2BTAF1CECR2 | |
| SCHEMBL24679 | 0.76 | — | — | |
| SCHEMBL1781918 | 0.76 | SMN1; SMN2 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL3756241 | 0.75 | — | — | |
| SCHEMBL3939405 | 0.74 | KAT2B (0.40) | KAT2BKDM4EALDH1A1 | |
| SCHEMBL774349 | 0.74 | TP53 (0.46) | POLBKDM1AALDH1A1 | |
| SCHEMBL771580 | 0.74 | EPHX2 (0.53) | KDM1A | |
| SCHEMBL1781485 | 0.73 | KDM1A (0.45) | POLBKAT2BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-02-06 | — | — | US | claimed |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-07-21 | — | — | US | claimed |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-09-10 | — | — | US | claimed |
| EP-2578584-B1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SI CHUAN UNIV (CN) | 2020-08-12 | — | — | EP | claimed |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | claimed |
| WO-2018049214-A9 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-10-18 | — | — | WO | claimed |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | claimed |
| WO-2018049214-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | claimed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | claimed |
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | claimed |
| CN-101163694-A | Imidaz0l0-5-yl-2-anil0-pyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB ASTRAZENECA UK (SE) | 2008-04-16 | — | — | CN | claimed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | claimed |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | PALUMED S.A. (FR) | 2007-03-15 | — | — | US | claimed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
| CN-1212696-A | Pyrimido [5, 4-d ] pyrimidines, medicaments containing these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1999-03-31 | — | — | CN | claimed |
| EP-0149840-B1 | Substituted 5,11-dihydro-6H-dibenz[b,e]azepin-6-ones, method for their preparation and these compounds containing medicines | Dr. Karl Thomae GmbH (DE) | 1989-04-26 | — | — | EP | claimed |
| US-4567178-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1986-01-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | POLB 1412/4885NCF1 944/4885KAT2B 2298/4885 |
| US-20190315743-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | POLB 1412/4885NCF1 944/4885KAT2B 2298/4885 |
| US-20070060558-A1 | Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, the synthesis and uses thereof as antibacterial agents | QARS1, QPCT, QTRT2 | POLB 872/4885NCF1 3999/4885KAT2B 3750/4885 |
| US-20180072718-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | POLB 1412/4885NCF1 944/4885KAT2B 2298/4885 |
| US-20200283434-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | POLB 1412/4885NCF1 944/4885KAT2B 2298/4885 |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | POLB 1412/4885NCF1 944/4885KAT2B 2298/4885 |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | POLB 1412/4885NCF1 944/4885KAT2B 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.